Abstract 381P
Background
Oral squamous cell carcinoma (OSCC) is highly prevalent in South-East Asia including Indonesia. Recurrence and early mortality in OSCC patients cause significant health burden. Subclassification of patients with high risks of locoregional recurrence and early death is beneficial for planning of treatment intensification and surveillance.
Methods
Formalin-fixed paraffin embedded (FFPE) tissues of OSCC were immuno-stained and analyzed for p16 expression. Semi-quantitative German scoring system for p16 was used. Risk factors and clinical parameters of OSCC patients were collected and compared to identify factors associated with recurrences and overall survival.
Results
OSCC recurrences and mortality were observed in in 82% and 78% patients (N=60) after a median follow-up of 32 months. Larger tumor size (T3 and T4) was significantly associated with both recurrences and mortality (OR = 3.967,95% CI = 1.007-15.618 and OR = 5.885, 95% CI = 1.541-22.47, respectively). Positive p16 staining was observed in 31% of tumors. Patients with p16 -positive expression were significantly associated with longer recurrence-free and overall survivals (medians of recurrence-free survivals were 31.2 vs 19.0 months, P=0.038 and overall survivals were 39.0 vs 28.8 months, P=0.048; respectively). Other clinical variables including early stages, negative cervical nodes, non-keratinizing tumors, and negative surgical margin status were significantly associated with longer recurrence-free and survivals (log-rank tests, P<0.05).
Conclusions
P16 -positive staining, early stages, positive cervical lymph node infiltration, and positive surgical margins are associated with better prognosis in OSCC patients. The study emphasizes the importance of early detection and the potential use of p16 and other clinical markers as prognostic markers in OSCC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
S. L. Anwar.
Funding
Universitas Gadjah Mada.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract